Real-World Impact of CAR-T Therapy on DLBCL: Insights & Future Research | Lisa Herms, PhD | #ASH24

Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD | #ASH24

Fludarabine vs. Bendamustine Lymphodepletion Prior to CAR-T for LBCL | Alaa Ali, MD | #ASH24

Treatment Outcomes for LBCL with Central Nervous System Involvement | Juan Alderuccio, MD | #ASH24

Venetoclax + Pola-R-CHP for High-Risk B-Cell Lymphoma | Catherine Diefenbach, MD | #ASH24

Glofit-R-ICE for Patients with Relapsed/Refractory DLBCL | Catherine Diefenbach, MD | #ASH24

Bispecific Antibody Use After CAR-T Failure for B-Cell Lymphoma | Megan Melody, MD, MS | #ASH24

Safety of CAR-T Therapy, Tisa-cel, for DLBCL | Christian Chabannon, MD, PhD | #ASH24

Moving the Diffuse Large B-Cell Lymphoma Field Forward | Matthew Matasar, MD | #ASH24

Safety & Efficacy of Odronextamab for DLBCL After CAR-T Failure | Matthew Matasar, MD | #ASH24

Ketogenic Diet During CAR-T Therapy for DLBCL | Christopher D'Angelo, MD | #ASH24

Boom-Boom Radiation as Bridging Therapy Prior to CAR-T for DLBCL | Christopher D'Angelo, MD | #ASH24

A Faster Tandem CAR T-Cell Product, Zamto-Cel Being Studied in DLBCL | Nirav Shah, MD, MSHP | #ASH24

Bispecific Antibody, AZD0486 Attacks a New Target in DLBCL | Sameh Gaballa, MD | #ASH24

Exploring Barriers to CAR T-Cell Therapy in Blood Cancer Patients | Yannis Valtis, MD | #ASH24

Glofitamab for Relapsed/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24

Promising Results for Odronextamab in Post CAR T Patients with DLBCL | Jennifer Crombie, MD | #ASH24